Tiziana Life Sciences Announces An Interview on Clinical Improvements for 2nd SPMS Patient
Tiziana Life Sciences (TLSA) announced positive clinical outcomes from its ongoing study on Foralumab for patients with Secondary Progressive Multiple Sclerosis (SPMS) during a recent interview. Conducted at Brigham and Women’s Hospital, the trial highlights the potential of Foralumab, the only fully human anti-CD3 mAb, in managing autoimmune diseases. The treatment has shown favorable safety profiles and effective immune response modulation. Tiziana focuses on innovative drug delivery technologies, aiming to improve patient outcomes by offering alternative routes for immunotherapy.
- Positive clinical results for Foralumab in SPMS treatment.
- Foralumab shows potential for improved safety and efficacy.
- Innovative drug delivery technologies could enhance treatment options.
- None.
NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug administration, today announces an interview with Chief Executive Officer and Chief Scientific Officer Kunwar Shailubhai, PhD and Proactive Investors discussing the positive clinical results from the second patient with Secondary Progressive Multiple Sclerosis (SPMS) in the ongoing study as part of an expanded access program at the Brigham and Women’s Hospital (BWH), Boston, MA.
About Foralumab
Foralumab (formerly NI-0401), the only entirely human anti-CD3 mAb, shows reduced release of cytokines after IV administration in healthy volunteers and in patients with Crohn's disease. In a humanized mouse model (NOD/SCID IL2γc-/-), it was shown that while targeting the T-cell receptor, orally administered foralumab modulates immune responses of the T-cells and enhances regulatory T-cells (Tregs), thereby providing therapeutic benefit in treating inflammatory and autoimmune diseases without the occurrence of potential adverse events usually associated with parenteral mAb therapy. Once a day treatment for 10 consecutive days with intranasal foralumab was not only well tolerated but it also produced strong clinical responses in COVID-19 patients. Based on these studies, the intranasal and oral administration of foralumab offers the potential to become a well-tolerated immunotherapy for autoimmune and inflammatory diseases by the induction of Tregs.
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana's innovative nasal, oral and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana's two lead candidates, intranasal foralumab, the only fully human anti-CD3 mAb, and milciclib, a pan-CDK inhibitor, have both demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana's technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.
Forward-Looking Statements
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
For further inquiries:
| Tiziana Life Sciences Ltd Hana Malik, Business Development, and Investor Relations Manager +44 (0) 207 495 2379 email: info@tizianalifesciences.com |
A video accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/459a0c78-4160-4592-b971-84ee0ff0ea53
FAQ
What are the latest updates on Tiziana Life Sciences (TLSA) regarding Foralumab?
How effective is Foralumab for SPMS according to Tiziana Life Sciences?
Where is Tiziana Life Sciences conducting its Foralumab study?
What is the significance of Foralumab in treating autoimmune diseases?
